Eloxx Pharmaceuticals (NASDAQ:ELOX) Upgraded by Guggenheim to “Strong-Buy” Rating

Eloxx Pharmaceuticals (NASDAQ:ELOX) was upgraded by equities research analysts at Guggenheim to a “strong-buy” rating in a report released on Monday,Zacks.com reports.

Eloxx Pharmaceuticals Trading Down 2.9%

Shares of Eloxx Pharmaceuticals stock opened at $11.65 on Monday. The firm has a market capitalization of $8.02 million, a PE ratio of -0.76 and a beta of -1,891.27. The stock has a fifty day simple moving average of $17.35. Eloxx Pharmaceuticals has a 12 month low of $11.61 and a 12 month high of $17.50.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc, formerly known as Sevion Therapeutics Inc, is based in WALTHAM, United States.